



FOUNDATION FUNDING OPPORTUNITIES: APRIL 16, 2021

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**Have you updated your MGH Researcher profile?
Go to <https://researchers.mgh.harvard.edu/> today!**

1. Quality Initiative Proposal for Funding, ACC Foundation (ACCF)/American College of Cardiology (ACC)

The ACC's Accreditation Services Foundation Committee supports cardiovascular performance improvement for United States-based healthcare organizations through its funding of quality initiative programs. Facilities interested in receiving funding will highlight the importance of ACC cardiovascular services accreditation as part of its overall clinical practice and quality.

Submitted proposals must aim to focus on one or more of the following objectives:

- Contribute to the evidence base for accreditation
- Develop or evaluate cardiovascular QI or PI that strengthens the accreditation process
- Provide opportunities for education that support quality or performance improvement projects
- Improve EMS systems of care in collaboration with community hospitals providing accreditation services
- Provide public health education to improve community measures/outcomes related to early recognition of heart attack symptoms and appropriate action steps

Citizenship: United States

Award Amount: \$100,000

Indirect Costs: None

Application Deadline: June 1, 2021



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

Website: <https://cvquality.acc.org/accreditation/quality-initiative-proposal>

2. Accelerating Drug Discovery for Frontotemporal Degeneration, Alzheimer's Drug Discovery Foundation (ADDF)

There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD) and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). Drug targets in the areas of inflammation and proteostasis will be considered high priority.

The RFP supports:

- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
- *In vivo* testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.

This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening. IND-enabling work is supported through ADDF's PACT RFP.

Citizenship: Unrestricted

Award Amount: \$100,000-\$150,000 for 1 year

Indirect Costs: None

LOI Deadline: May 28, 2021

(Invited) Proposal Deadline: July 30, 2021

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd>

3. Seed Grant Program, The Foundation for OCD Research **NEW!**

FFOR is seeking applications for innovative, potentially high-impact pre-clinical, translational or clinical research from investigators around the world. We seek to support projects that have the potential to significantly advance the understanding of the pathophysiology of OCD and/or improve the treatment of severe OCD.

FFOR seeks applications covering a broad range of topics and approaches that have the potential to dramatically change understanding of OCD pathophysiology or dramatically improve its treatment. Virtually any pre-clinical/basic science, translational or clinical research

topic will be considered. Cross-disciplinary collaborative projects are encouraged. Examples of relevant research include, but are not limited to studies that aim to:

- Discover the molecular, cellular, synaptic, or circuit basis of prominent OCD symptoms in model organisms or humans.
- Identify and/or test pharmacological and non-pharmacological therapeutic targets.
- Advance biomarker development for OCD to improve diagnoses and/or treatment outcomes.
- Explore the role of the immune system or microbiome in OCD.
- Develop new models or refine existing models of OCD.

Eligibility requirements (partial list):

- Applicants must have principal investigator (PI) status at their home institutions at the rank of Assistant Professor (or equivalent) or above.
- A maximum of five awards will be given. At least two will be given to junior faculty (or equivalents)
- Awardees will be expected to attend the annual retreat of FFOR's participating scientists.

Citizenship: Unspecified

Award Amount: \$600,000 paid over 3 years

Indirect Costs: 10%

LOI Deadline: June 15, 2021

(Invited) Proposal Deadline: TBD

Website: <https://www.ffor.org/grants>

4. HD Human Biology Project, Huntington's Disease Society of America

The Human Biology Project was launched in 2013 with the goal of fostering innovative research in collaboration with HD clinics to better understand the biology of Huntington's disease as it occurs in humans. HDSA encourages researchers to consider one of HDSA's 50 Centers of Excellence as a potential collaborator, but applicants may propose to work with any HD clinic around the world.

Eligibility requirements (partial list):

- Preference given to young postdoctoral and clinical investigators (PhD and/or MDs) who are not yet independent
- Innovative ideas from non-scientists will also be accepted and encouraged
- Applications are welcomed and encouraged from individuals from other areas of research and health care (e.g., biostatisticians, physical therapists, etc).
- Mentors: If the applicant is a post-doctoral or clinical research fellow, a mentor must be identified before applying for the HD Human Biology Project. All mentors must have a PhD and/or MD/DO degree and be scientific investigators with primary appointments at

academic, public or private research institutions. Collaborations between multiple HD clinics are strongly encouraged.

Citizenship: Unrestricted

Award Amount: \$75,000-\$150,000 paid over 1-2 years

Indirect Costs: None

LOI Deadline: May 7, 2021

Application Deadline: July 9, 2021

Website: <http://hdsa.org/hd-research/hd-human-biology-project/>

5. Addressing Primary Immunodeficiencies within Minority/Underserved Populations, Pfizer Global Medical Grants (GMG) **NEW!**

Primary immunodeficiencies occur in all patient populations but the diagnoses are infrequently made in minority populations in the US. These disparities have been noted in several studies.

Through this RFP, it is our intent to support patient and provider educational programs on the awareness, diagnosis, and treatment of primary immunodeficiencies within minority/underserved populations.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: United States

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: May 25, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

6. Enzalutamide in the Treatment of Prostate Cancer, Pfizer Global Medical Grants (GMG) **NEW!**

The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted.

The following are selected priority areas to encourage the development of novel treatment

approaches because of their ability to impact the unmet needs for patients with potentially lethal prostate cancer:

1. Earlier disease states
2. Treatment and biology of oligometastatic disease
3. Populations with unique vulnerabilities
4. Innovative treatment strategies
5. Specific disease settings in which enzalutamide may offer value
6. Next generation imaging
7. Biomarkers of enzalutamide response (including imaging)
8. Strategies to improve the therapeutic index of enzalutamide

Citizenship: United States

Award Amount: Unspecified

Indirect Costs: 28%

LOI Deadline: May 14, 2021

(Invited) Application Deadline: August 1, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

7. Patient and Caregiver Awareness of Drug Resistant Infections, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support will focus on patient and caregiver awareness on the importance of appropriate use of intravenous or home infusion anti-infectives (antibiotics or antifungals) as a part of chronic disease management, including oncology, diabetes, hematology, immunology, renal disorders, rheumatology, pulmonology, and patients with long-term hospital stays.

Projects that will be considered should include a focus on patient and caregiver awareness and education that will support the initial diagnosis, treatment of bacterial and/or fungal infections and also increase patient awareness of the need for appropriate use of anti-infectives and prevention measures. Programs that strive to reduce health disparities by following principles of health literacy will be prioritized along with programs that aid in a close coordination of care between HCPs and patients.

All activity types will be considered, though given the current pandemic circumstances, virtual and digital activities will be prioritized. This includes applications to repurpose existing educational resources into easy-to-use and easy-to-access delivery formats. We will also consider applications repurposing education or training resources that currently exist in one language but could be modified and translated to other languages and rolled out in different geographies.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: United States or Europe

Award Amount: \$25,000-\$100,000

Indirect Costs: 28%

Application Deadline: May 19, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

8. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant Program, Pfizer Global Medical Grants (GMG) **NEW!**

The diagnosis of ATTR-CM is complex and often requires patients to undergo many diagnostic procedures with multiple specialists. The nurse navigator is an important member of the healthcare team who provides care in a highly supportive and personal manner and helps to guide and support patients and their families through the patient diagnostic and treatment journey.

Projects that will be considered for funding will focus on supporting the development of nurse navigator programs, including training, in order to improve the quality of care for ATTR-CM patients.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: United States

Award Amount: \$75,000

Indirect Costs: 28%

Application Deadline: June 15, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

9. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support will focus on several or one specified area:

- Early identification, evaluation, diagnosis, prognosis & treatment
- Study of hereditary ATTR genotypes and phenotypes
 - Non-Val30Met genotypes
 - Val122Ile, Thr60Ala, Val30Met, and others
- Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
- Use of tafamidis in the clinical setting (i.e. real-world evidence)

Award Amount: \$75,000

Indirect Costs: 28%

Application Deadline: June 9, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>